http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass and Overall Skin Repair Outcomes in Preclinical Study
-
VYNE Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021
-
Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflammatory Cytokines in Preclinical Studies
-
VYNE Therapeutics Announces Formation of Scientific Advisory Board
-
VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
-
VYNE Therapeutics Announces its China Partner’s Enrollment of First Patient in Phase 3 Study of AMZEEQ® in Patients with Moderate to Severe Acne
-
VYNE Therapeutics to Present at the Cantor Fitzgerald Investment Conference
-
VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference
-
VYNE Therapeutics Reports Second Quarter 2021 Financial Results and Announces New Strategic Direction to Develop Treatments for Immunological and Inflammatory Diseases
-
VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory Conditions with In4Derm Limited
-
VYNE Therapeutics Announces Approval of AMZEEQ® (Minocycline) and ZILXI® (Minocycline) in Chinese Economic Pilot Zone
-
VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021
-
VYNE Therapeutics Announces Initiation of Investigator Initiated Trial Evaluating AMZEEQ® (Minocycline) with Oral Isotretinoin in Patients with Moderate to Severe Acne
-
VYNE Therapeutics to Participate in the 2nd Annual JAK Inhibitors Drug Development Digital Event
-
VYNE Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
-
VYNE Therapeutics to Report First Quarter 2021 Financial Results on May 6, 2021
-
VYNE Therapeutics to Present at Upcoming Virtual Investor Conferences
-
VYNE Therapeutics Reports Year-End 2020 Financial Results and Provides Business Update
-
VYNE Therapeutics to Present at the Cowen 41st Annual Health Care Conference
-
VYNE Therapeutics (VYNE) Announces Development Program for FMX114 Combination Topical Gel for Mild-to-Moderate Atopic Dermatitis
-
VYNE Therapeutics Announces Development Program for FMX114 Combination Topical Gel for Mild-to-Moderate Atopic Dermatitis
-
VYNE Therapeutics to Report Financial Results for the Year Ended December 31, 2020 on March 4
-
VYNE Therapeutics (VYNE) Announces 1-for-4 Reverse Stock Split
-
VYNE Therapeutics Announces Reverse Stock Split
-
VYNE Therapeutics (VYNE) Announces FDA Approval of AMZEEQ Label Update
-
VYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label Update
-
VYNE Therapeutics Announces Closing of $50 Million Registered Direct Offering of Common Stock and Provides Corporate Update
-
VYNE Therapeutics (VYNE) Announces $50 Million Registered Direct Offering of Common Stock
-
VYNE Therapeutics Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
-
VYNE Therapeutics (VYNE) Announces Contract Execution for AMZEEQ and ZILXI with Major Pharmacy Benefit Management Company
-
VYNE Therapeutics Announces Contract Execution for AMZEEQ® (minocycline) and ZILXI® (minocycline) with Major Pharmacy Benefit Management (PBM) Company
-
VYNE Therapeutics to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event this Week
-
VYNE Therapeutics (VYNE) Announces Successful End-of-Phase 2 Meeting with FDA for FCD105 in Acne
-
VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for FCD105 in Acne
-
VYNE Therapeutics Added to Nasdaq Biotechnology Index
-
VYNE Therapeutics (VYNE) Announces New U.S. Patent Expiring in 2037 for AMZEEQ® (minocycline) topical foam, 4%
-
VYNE Therapeutics Announces New U.S. Patent Expiring in 2037 for AMZEEQ® (minocycline) topical foam, 4%
-
VYNE Therapeutics (VYNE) Announces Publication of Long-term Safety & Efficacy Data for ZILXI™ (minocycline) topical foam, 1.5% in the Journal of Clinical and Aesthetic Dermatology
-
VYNE Therapeutics Announces Publication of Long-term Safety & Efficacy Data for ZILXI™ (minocycline) topical foam, 1.5% in the Journal of Clinical and Aesthetic Dermatology
-
VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference
-
VYNE Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
-
VYNE Therapeutics to Report Third Quarter 2020 Financial Results on November 5th
-
VYNE Therapeutics (VYNE) Announces Covered Status for ZILXI with Express Scripts
-
VYNE Therapeutics Announces Covered Status for ZILXI™ (minocycline) with Express Scripts
-
VYNE Therapeutics Announces Covered Status for ZILXI™ (minocycline) with Express Scripts
-
VYNE Therapeutics Announces ZILXI™ (minocycline) topical foam, 1.5% Available in Pharmacies Nationwide on October 1st
-
VYNE Therapeutics Announces ZILXI™ (minocycline) topical foam, 1.5% is Available in Pharmacies Nationwide Today, October 1st
-
VYNE Therapeutics to Host Physician Symposium on AMZEEQ® and ZILXI™
-
VYNE Therapeutics (VYNE) Announces Patrick G. LePore to Board
-
VYNE Therapeutics Announces the Appointment of Patrick G. LePore to its Board of Directors
